Skip to main content
. Author manuscript; available in PMC: 2017 Apr 5.
Published in final edited form as: Nat Rev Cancer. 2016 Apr 15;16(5):275–287. doi: 10.1038/nrc.2016.36

Figure 4. Multifactorial biomarkers of clinical response to PD1 pathway blockade.

Figure 4

Tumour mutational load, the intensity of intratumoural CD8+ T cell infiltrates and tumour programmed cell death ligand 1 (PDL1) expression have each been proposed as distinct biomarkers of response to anti-programmed cell death protein 1 (PD1) PDL1 therapies. However, these factors are functionally interrelated and are often found coordinately in individual tumour specimens. Multifactorial biomarker panels incorporating these and other variables may provide stronger predictive value than individual markers for therapeutic outcomes.